Physician profile
Jan Rasnake
NPI 1356651897
$4,880.43
in general payments reported to CMS, 2019-2025
38 companies · $918 in 2025
The $918 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $751 · 2022: $601 · 2023: $1,107 · 2024: $1,503 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,528.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $694.79 | 2021-2025 | |
| Novo Nordisk INC | $691.88 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $451.29 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Axsome Therapeutics, INC. | $386.07 | 2023-2025 | Auvelity, Sunosi |
| Pfizer INC. | $252.13 | 2021-2025 | |
| Amgen INC. | $235.44 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $219.30 | 2021-2025 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $179.42 | 2024-2025 | Fanapt, Hetlioz |
| Corium, LLC | $168.48 | 2023-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.63 | 2023-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.54 | 2021-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $124.05 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Collegium Pharmaceutical, INC. | $117.66 | 2025 | Jornay Pm |
| Lilly USA, LLC | $110.89 | 2021-2024 | Mounjaro |
| Takeda Pharmaceuticals U.S.A., INC. | $102.27 | 2021-2024 | Trintellix |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $82.31 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $74.44 | 2023-2025 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $67.79 | 2023-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $58.32 | 2023 | Rexulti |
| Astellas Pharma US INC | $57.77 | 2023-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $51.24 | 2024-2025 | Austedo Xr, Austedo Xr |
| Esperion Therapeutics, INC. | $48.30 | 2024-2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $47.71 | 2021 | |
| Currax Pharmaceuticals LLC | $47.40 | 2022-2023 | Contrave, Onzetra Xsail |
| Inspire Medical Systems, INC. | $40.53 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $32.84 | 2024 | Voquezna |
| Insulet Corporation | $30.64 | 2025 | Omnipod |
| E.R. Squibb & Sons, L.L.C. | $28.60 | 2022 | |
| Alkermes, INC. | $28.40 | 2023 | Lybalvi |
| Tandem Diabetes Care, INC. | $27.59 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Genentech USA, INC. | $21.54 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.81 | 2023 | |
| Merck Sharp & Dohme LLC | $16.38 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Ardelyx, INC. | $15.40 | 2025 | Ibsrela |
| Lundbeck LLC | $15.13 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $14.78 | 2025 | Nuzyra, Xhance |
| Novartis Pharmaceuticals Corporation | $14.15 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Rasnake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.